M. Dankner

发表

The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers

P. Siegel, L. Garzia, M. Guiot, 2021, Cancers.

CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis.

A. Mes-Masson, F. Saad, P. Siegel, 2019, American Journal of Pathology.

CEACAM1 as a multi-purpose target for cancer immunotherapy

N. Beauchemin, S. Gray-Owen, R. Blumberg, 2017, Oncoimmunology.

Invasive growth associated with Cold-Inducible RNA-Binding Protein expression drives recurrence of surgically resected brain metastases.

J. Ragoussis, Jean Monlong, G. Bourque, 2021, Neuro-oncology.

Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’

A. Rose, M. Dankner, 2018, British Journal of Cancer.

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors

S. Shah, S. Aparicio, A. Wan, 2020, Communications Biology.

Radiomics as an emerging tool in the management of brain metastases

P. Siegel, K. Petrecca, M. Dankner, 2022, Neuro-oncology advances.

Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors

K. Flaherty, D. Cescon, M. Gerlinger, 2022, JCO precision oncology.

p66ShcA functions as a contextual promoter of breast cancer metastasis

J. Ursini-Siegel, P. Siegel, I. Watson, 2020, Breast Cancer Research.

A survey of health care professionals and oncology patients at the McGill University Health Centre reveals enthusiasm for establishing a postmortem rapid tissue donation program.

N. Bertos, P. Siegel, N. Bouganim, 2019, Current oncology.

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy

A. Roulston, P. Siegel, Morag Park, 2018, Anti-cancer drugs.

Single-cell spatial immune landscapes of primary and metastatic brain tumours

P. Siegel, Morag Park, I. Watson, 2023, Nature.

Spatially mapping the immune landscape of melanoma using imaging mass cytometry

H. Najafabadi, A. Mes-Masson, Luke Anderson-Trocmé, 2022, Science Immunology.

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

P. Siegel, I. Watson, A. Rose, 2018, Oncogene.

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.

R. Alkallas, P. Siegel, I. Watson, 2022, Cell reports.

Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology.

M. Dankner, 2018, JCO precision oncology.

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas

A. Protopopov, D. Hogg, P. Siegel, 2018, Clinical Cancer Research.

STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer

J. Ursini-Siegel, C. Chabot, C. Kleinman, 2021, Nature Communications.

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors

D. Cescon, M. Gerlinger, J. Sosman, 2022, medRxiv.

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors

A. Wan, N. Bertos, P. Siegel, 2020, Communications Biology.

BRAF Mutation Class and Clinical Outcomes—Letter

A. Rose, M. Dankner, 2019, Clinical Cancer Research.

Post‐mortem tissue donation programs as platforms to accelerate cancer research

N. Bouganim, M. Dankner, B. Issa-Chergui, 2020, The journal of pathology. Clinical research.

The relevance of surgical status in nodular leptomeningeal metastasis patient outcomes.

Sarah M. Maritan, M. Dankner, 2021, Neuro-oncology.

Non-small-cell lung cancer: how to manage BRAF-mutated disease

M. Tiseo, G. Guaitoli, F. Facchinetti, 2023, Drugs in context.

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

S. Hofer, R. Soffietti, A. Seidman, 2023, Breast.

A. Rose, M. Dankner, 2018, British Journal of Cancer.

Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinations

P. Siegel, I. Watson, K. Petrecca, 2018 .

75 million syringes but nothing to put in them: what is Canada’s plan for a COVID-19 vaccine?

Mackenzie A. Michell-Robinson, M. Dankner, 2020 .

The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers

D. Cescon, A. Spreafico, M. Dankner, 2023, bioRxiv.

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss

Sarah M. Maritan, E. Ichihara, M. Dankner, 2024, Heliyon.

The evolving treatment landscape for BRAF-mutated non-small cell lung cancer

M. Dankner, A. Rose, Jennifer Maxwell, 2023, Translational Lung Cancer Research.

Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers

M. Dankner, Anna-Maria Lazaratos, A. Elkrief, 2024, medRxiv.

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.

M. Dankner, I. Soria-Bretones, A. Rose, 2024, Nature reviews. Cancer.

Neoadjuvant Chemoimmunotherapy for NSCLC

B. Sepesi, T. Cascone, M. Dankner, 2024, JAMA oncology.